E. Ohman J:or Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

E. Ohman J:or Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.38M	Hold	4,584	–	–	0.03%	259
2026 Q1	$1.52M	Hold	4,584	–	–	0.04%	220
2025 Q4	$1.82M	Sell	4,584 -1,116	-20%	-$494K	0.04%	200
2025 Q3	$2.6M	Hold	5,700	–	–	0.06%	150
2025 Q2	$1.86M	Sell	5,700 -100	-2%	-$27.7K	0.05%	183
2025 Q1	$1.57M	Sell	5,800 -300	-5%	-$77.1K	0.04%	204
2024 Q4	$1.44M	Buy	6,100 +700	+13%	+$184K	0.03%	221
2024 Q3	$1.49M	Buy	+5,400	New	+$1.41M	0.04%	204
2023 Q3	–	Sell	-2,000	Closed	-$380K	–	420
2023 Q2	$380K	Hold	2,000	–	–	0.01%	390
2023 Q1	$401K	Buy	+2,000	New	+$420K	0.02%	380
2022 Q1	–	Sell	-6,400	Closed	-$1.09M	–	427
2021 Q4	$1.09M	Buy	+6,400	New	+$1.19M	0.03%	286
2021 Q2	–	Sell	-2,500	Closed	-$353K	–	463
2021 Q1	$353K	Hold	2,500	–	–	0.01%	392
2020 Q4	$325K	Hold	2,500	–	–	0.01%	379
2020 Q3	$364K	Buy	+2,500	New	+$355K	0.02%	328
2020 Q2	–	Sell	-2,300	Closed	-$250K	–	432
2020 Q1	$250K	Sell	2,300 -900	-28%	-$104K	0.02%	328
2019 Q4	$369K	Buy	+3,200	New	+$319K	0.02%	351
2018 Q2	–	Sell	-2,200	Closed	-$262K	–	379
2018 Q1	$262K	Hold	2,200	–	–	0.02%	394
2017 Q4	$280K	Buy	+2,200	New	+$276K	0.02%	417
2016 Q4	–	Sell	-1,600	Closed	-$108K	–	552
2016 Q3	$108K	Hold	1,600	–	–	0.02%	495
2016 Q2	$88.8K	Hold	1,600	–	–	0.01%	496
2016 Q1	$100K	Hold	1,600	–	–	0.02%	481
2015 Q4	$151K	Hold	1,600	–	–	0.03%	417
2015 Q3	$129K	Hold	1,600	–	–	0.03%	430
2015 Q2	$192K	Buy	+1,600	New	+$191K	0.04%	367

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

E. Ohman J:or Asset Management's ALNY Position: Q2 2026 in Review

E. Ohman J:or Asset Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 4,584 shares worth $1.38M. The position accounts for 0.03% of the portfolio, ranked #259.

E. Ohman J:or Asset Management first reported a position in ALNY in Q2 2015 and has held it in 24 quarters since. The position peaked at $2.6M in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

E. Ohman J:or Asset Management held 4,584 shares of Alnylam Pharmaceuticals worth $1.38M as of Q2 2026.
E. Ohman J:or Asset Management left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
Alnylam Pharmaceuticals made up 0.03% of E. Ohman J:or Asset Management's portfolio in Q2 2026, its #259 holding.
E. Ohman J:or Asset Management first reported a position in Alnylam Pharmaceuticals in Q2 2015 and has held it in 24 quarters since.
E. Ohman J:or Asset Management's Alnylam Pharmaceuticals position peaked at $2.6M in Q3 2025.
793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on E. Ohman J:or Asset Management's 13F filing for Q2 2026, filed 10 Jul 2026.